Advertisement


Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415

2015 ASTRO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).



Related Videos

Lung Cancer
Pain Management

Brian D. Kavanagh, MD, on Improving Value and Elevating the Patient Care Experience

Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients with bone metastases (Abstracts 2, 8, LBA6663).

Breast Cancer

Reshma Jagsi, MD, DPhil, on the Initial Results of the TBCRC 024 Study on Breast Cancer

Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).

Lung Cancer

Stephen G. Chun, MD, on NSCLC: Results From NRG Oncology/RTOG 0617

Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).

Pancreatic Cancer
Hepatobiliary Cancer

Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers

Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).

Breast Cancer

Jay Harris, MD, on Making Sense of Conflicting Data on Breast Irradiation

Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.

Advertisement

Advertisement




Advertisement